Liu Chih-Yu, Chen Rou-Tsern, Shu Chin-Chung, Lin Shu-Yung
Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
College of Medicine, National Taiwan University, Taipei, Taiwan.
Sci Rep. 2025 Apr 27;15(1):14709. doi: 10.1038/s41598-025-97517-y.
Limited research has been conducted on the prevalence and factors associated with extended drug-susceptible tuberculosis (TB) treatment. A retrospective study enrolled drug-susceptible TB patients (January 2018 to December 2020) from a hospital's registry to analyze prevalence, reasons, and factors for extended treatment (≥ 9 months) compared with standard course. Analyzing 221 TB patients, 80 patients received extended treatment. The extended group showed higher hepatitis B infection rates (12.5% vs. 5%, p = 0.043), recent cancer treatment (18.8% vs. 8.5%, p = 0.025), more adverse drug events (ADEs) (grade 3 or more severe ADEs 27.5% vs. 11.3%, p = 0.003), and treatment interruptions (46.3% vs. 18.4%, p < 0.001). Logistic regression highlighted hepatitis B infection (AOR 3.10, p = 0.039), recent cancer treatment (AOR 3.09, p = 0.013), and post-treatment elevated aminotransferase (AOR 2.40, p = 0.014) as independent factors for extended treatment. Extended anti-TB treatment affects 28.7% of patients, with host characteristics and adverse drug effects playing a role in treatment duration. Integrating these factors into treatment strategies is vital for optimal patient care.
关于广泛耐药结核病（TB）治疗的患病率及相关因素的研究有限。一项回顾性研究纳入了一家医院登记处2018年1月至2020年12月期间的药敏结核病患者，以分析与标准疗程相比延长治疗（≥9个月）的患病率、原因和因素。分析221例结核病患者，其中80例接受了延长治疗。延长治疗组的乙肝感染率更高（12.5%对5%，p = 0.043）、近期接受过癌症治疗（18.8%对8.5%，p = 0.025）、药物不良事件（ADEs）更多（3级或更严重的ADEs为27.5%对11.3%，p = 0.003）以及治疗中断情况更多（46.3%对18.4%，p < 0.001）。逻辑回归强调乙肝感染（比值比3.10，p = 0.039）、近期癌症治疗（比值比3.09，p = 0.013）以及治疗后转氨酶升高（比值比2.40，p = 0.01）是延长治疗的独立因素。延长抗结核治疗影响28.7%的患者，宿主特征和药物不良反应在治疗持续时间中起作用。将这些因素纳入治疗策略对优化患者护理至关重要。
